# Hymater

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hymater

- Industry: Materials
- Headquarters: Ningbo, China
- Website: www.hymater.com
- Latest round: Series A (Jan 18, 2024)
- Investors on record: 2

## About

Based in Ningbo, China, and founded in 2017, Hymater operates as an inorganic membrane manufacturer, specializing in R&D and production of specialty separation membranes and membrane engineering. It has more than 1,000 square meters of research and development base and 2,000 square meters of production base. The company has acquired the title of National Outstanding Enterprise and Zhejiang Province Leading Innovation and Entrepreneurship Team. The founder, Yanshuo Li, graduated from Dalian Institute of Chemical Physics, Chinese Academy of Sciences. In January 2024, Hymater closed series A funding.

The company has self-developed Plug-In PIER® (Productivity Increasement and Energy-consumption Reduction) and ONPS® (On-site NMP Purification System) techniques. ONP technique can be used for on-site recovery and refining of NMP solvents in the lithium industry. Its products include zeolite molecular sieve membrane, MOF molecular sieve membrane, carbon molecular sieve membrane, osmosis vaporization separation membrane, and other special membranes. The products can be used in lithium, fuel ethanol, fine chemicals, pharmaceuticals, and other fields. Its clients include Wanhua Chemical, Yangzi Petrochemical, COFCO, etc.

Hymater plans to further expand its production capacity and develop more membrane product categories. The company will also pay more attention to R&D and market investment in industrial scenarios such as NMP on-site refining and reuse in the lithium industry.

## Funding rounds

- Series A, Jan 18, 2024 — FG Venture, Hangzhou Xiaochi Private Equity Fund Management

## Investors

- FG Venture (https://capitalatlas.ai/funds/fg-venture) — Series A
- Hangzhou Xiaochi Private Equity Fund Management (https://capitalatlas.ai/funds/hangzhou-xiaochi-private-equity-fund-management) — Series A